TNFRSF9 and neoplasm: The independent activity of both IL-15 fusions [45, 46] and 4-1BB agonists [47–50] has been demonstrated for in vivo tumor inhibition; however, there is a clear benefit for the simultaneous presentation of IL-15 and 4-1BBL in a single fusion protein in a tumor mouse model in vivo [9].